Clinical Trials Browser

Phase 1/2 × Active not recruiting × olaparib × Clear all

Breast Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Small Cell Lung Carcinoma

NCT02484404 2026-03-25

Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...

Phase 1/2 Active not recruiting

268 enrolled

BreastGastrointestinal

Breast Neoplasms, Colorectal Neoplasms

NCT01116648 2026-03-05

Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer

Phase 1/2 Active not recruiting

155 enrolled 34 charts

BreastGynecologic

Fallopian Tube Neoplasms, Triple Negative Breast Neoplasms

NCT02264678 2026-02-20

Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents

Phase 1/2 Active not recruiting

357 enrolled

Gynecologic

Ovarian Neoplasms

NCT03317392 2026-02-19

Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With Bone Metastasis

Phase 1/2 Active not recruiting

145 enrolled

Genitourinary

Prostatic Neoplasms

NCT03085147 2026-02-12

A Dye for the Detection of Cancer of the Tongue and Mouth

Phase 1/2 Active not recruiting

23 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT04728230 2025-12-18

Olaparib and Durvalumab With Carboplatin, Etoposide, and/or Radiation Therapy for the Treatment of Extensive-Stage Small Cell Lung Cancer, PRIO Trial

Phase 1/2 Active not recruiting

63 enrolled

Thoracic

Lung Neoplasms

NCT03212742 2025-12-04

OLA-TMZ-RTE-01

Phase 1/2 Active not recruiting

91 enrolled

CNS

Glioma

NCT05898399 2025-10-15

Study of ART6043 in Advanced/Metastatic Solid Tumors Patients

Phase 1/2 Active not recruiting

220 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT02571725 2025-05-23

PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer

Phase 1/2 Active not recruiting

50 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

NCT03594396 2025-04-17

Window of Opportunity Trial of Neoadjuvant Olaparib and Durvalumab for Triple Negative or Low ER+ Breast Cancer

Phase 1/2 Active not recruiting

54 enrolled

Breast

Breast Neoplasms

Clinical Trials

MEDIOLA

Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...

Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer

Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents

Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With Bone Metastasis

A Dye for the Detection of Cancer of the Tongue and Mouth

Olaparib and Durvalumab With Carboplatin, Etoposide, and/or Radiation Therapy for the Treatment of Extensive-Stage Small Cell Lung Cancer, PRIO Trial

OLA-TMZ-RTE-01

Study of ART6043 in Advanced/Metastatic Solid Tumors Patients

PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer

Window of Opportunity Trial of Neoadjuvant Olaparib and Durvalumab for Triple Negative or Low ER+ Breast Cancer